Department of Pharmacology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
J Pharmacol Exp Ther. 2013 Jul;346(1):31-7. doi: 10.1124/jpet.112.202275. Epub 2013 Apr 17.
The serine protease chymase has been reported to generate intracardiac angiotensin-II (Ang-II) from Ang-I as well as an intermediate precursor of endothelin-1 (ET-1), ET-1 (1-31) from Big-ET-1. Although humans possess only one chymase, several murine isoforms are documented, each with its own specific catalytic activity. Among these, mouse mast cell protease 4 (mMCP-4) is the isoform most similar to the human chymase for its activity. The aim of this study was to characterize the capacity of mMCP-4 to convert Big-ET-1 into its bioactive metabolite, ET-1, in vitro and in vivo in the mouse model. Basal mean arterial pressure did not differ between wild-type (WT) and mMCP-4(-/-) mice. Systemic administration of Big-ET-1 triggered pressor responses and increased blood levels of immunoreactive (IR) ET-1 (1-31) and ET-1 that were reduced by more than 50% in mMCP-4 knockout (-/-) mice compared with WT controls. Residual responses to Big-ET-1 in mMCP-4(-/-) mice were insensitive to the enkephalinase/neutral endopeptidase inhibitor thiorphan and the specific chymase inhibitor TY-51469 {2-[4-(5-fluoro-3-methylbenzo[b]thiophen-2-yl)sulfonamido-3-methanesulfonylphenyl]thiazole-4-carboxylic acid}. Soluble fractions from the lungs, left cardiac ventricle, aorta, and kidneys of WT but not mMCP-4(-/-) mice generated ET-1 (1-31) from exogenous Big-ET-1 in a TY-51469-sensitive fashion as detected by high-performance liquid chromatography/ matrix-assisted laser desorption/ionization-mass spectrometry. Finally, pulmonary endogenous levels of IR-ET-1 were reduced by more than 40% in tissues derived from mMCP-4(-/-) mice compared with WT mice. Our results show that mMCP-4 plays a pivotal role in the dynamic conversion of systemic Big-ET-1 to ET-1 in the mouse model.
糜蛋白酶已被报道能从血管紧张素 I(Ang-I)生成心脏内的血管紧张素 II(Ang-II)以及内皮素-1(ET-1)的中间前体 Big-ET-1 到 ET-1(1-31)。尽管人类只拥有一种糜蛋白酶,但已有多种鼠同型酶被记录,每种都具有自己特定的催化活性。在这些同型酶中,鼠肥大细胞蛋白酶 4(mMCP-4)因其活性与人类糜蛋白酶最为相似,是最相似的同型酶。本研究旨在研究 mMCP-4 在体外和体内转化 Big-ET-1 为其生物活性代谢物 ET-1 的能力,研究模型为鼠。野生型(WT)和 mMCP-4(-/-)小鼠的基础平均动脉压无差异。全身给予 Big-ET-1 可引发升压反应,并增加免疫反应性(IR)ET-1(1-31)和 ET-1 的血液水平,这些水平在 mMCP-4 敲除(-/-)小鼠中比 WT 对照降低了 50%以上。在 mMCP-4(-/-)小鼠中,Big-ET-1 的残留反应对脑啡肽酶/中性内肽酶抑制剂硫醇和特异性糜蛋白酶抑制剂 TY-51469{2-[4-(5-氟-3-甲基苯并[b]噻吩-2-基)磺酰胺基-3-甲磺酰基苯基]噻唑-4-羧酸}不敏感。WT 而不是 mMCP-4(-/-)小鼠的肺、左心室、主动脉和肾脏的可溶性部分以 TY-51469 敏感的方式从外源性 Big-ET-1 生成 ET-1(1-31),如高效液相色谱/基质辅助激光解吸/电离质谱所检测到的。最后,与 WT 小鼠相比,mMCP-4(-/-)小鼠组织中的肺内源性 IR-ET-1 水平降低了 40%以上。我们的结果表明,mMCP-4 在鼠模型中在全身 Big-ET-1 向 ET-1 的动态转化中起着关键作用。